Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study is a clinical trial[1].
Key Facts
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study is in the country of United States[2].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's instance of is recorded as clinical trial[3].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's start time is recorded as +2012-02-29T00:00:00Z[4].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's end time is recorded as +2016-01-31T00:00:00Z[5].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's sponsor is recorded as Massachusetts General Hospital[6].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's main subject is recorded as cardiovascular disease risk factor[7].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's main subject is recorded as atherosclerosis[8].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's main subject is recorded as psoriasis[9].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's number of participants is recorded as {'unit': '1', 'amount': '+29'}[10].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's title is recorded as Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study[11].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's short name is recorded as MMAPPS[12].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[13].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's ClinicalTrials.gov ID is recorded as NCT01522742[14].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}[15].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's research intervention is recorded as etanercept[16].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's research site is recorded as Massachusetts General Hospital[17].
- Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study's study type is recorded as observational study[18].